Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2016
At a glance
- Drugs AB SA01 (Primary)
- Indications Staphylococcal infections
- Focus Adverse reactions
- Sponsors AmpliPhi Biosciences Corporation
- 05 Dec 2016 Results published in an AmpliPhi Biosciences Corporation media release.
- 13 Sep 2016 AmpliPhi expects to report final results of the trial by the end of 2016, according to a company media release.
- 13 Sep 2016 Topline results published in the Media Release